BioNTech Buys FDA Priority Review Voucher for $205M

The price tag is the signal here: BioNTech is paying up to compress regulatory timelines on a future filing, which suggests the company sees timing as a competitive variable rather than a back-office detail. Voucher purchases are a market in themselves, and a $205 million print is a useful reference point for how the industry values speed at the FDA. What's worth watching is whether this reflects a specific near-term application or a broader habit of buying optionality, and whether voucher pricing holds at this level as more buyers enter.